Download PDF
Thromb Haemost 1995; 74(04): 1079-1087
DOI: 10.1055/s-0038-1649885
Original Article
Coagulation
Schattauer GmbH Stuttgart

Characterization of a cDNA for Rhesus Monkey Protein C Inhibitor – Evidence for N-Terminal Involvement in Heparin Stimulation

Klaus-P Radtke
Department of Molecular and Experimental Medicine, Department of Vascular Biology, The Scrlpps Research Institute, La Jolla, California, CA, USA
,
José A Fernández
Department of Molecular and Experimental Medicine, Department of Vascular Biology, The Scrlpps Research Institute, La Jolla, California, CA, USA
,
Bruno O Villoutreix
Department of Molecular and Experimental Medicine, Department of Vascular Biology, The Scrlpps Research Institute, La Jolla, California, CA, USA
,
Judith S Greengard
Department of Molecular and Experimental Medicine, Department of Vascular Biology, The Scrlpps Research Institute, La Jolla, California, CA, USA
,
John H Griffin
Department of Molecular and Experimental Medicine, Department of Vascular Biology, The Scrlpps Research Institute, La Jolla, California, CA, USA
› Author Affiliations
Further Information

Publication History

Received 14 July 1994

Accepted 29 June 1995

Publication Date:
09 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

cDNAs for protein C inhibitor (PCI) were cloned from human and rhesus monkey[ 1 ] liver RNAs by reverse transcription and polymerase chain reaction (PCR) amplification. Sequencing showed that rhesus monkey and human PCI cDNAs were 93% identical. Predicted amino acid sequences differed at 26 of 387 residues. Pour of these differences (T352M, N359S, R362K, L3631) were in the reactive center loop that is important for inhibitory specificity, and two were in the N-terminal helix (M8T, E13K) that is implicated in glycosaminoglycan binding. PCI in human or rhesus monkey plasma showed comparable inhibitory activity towards human activated protein C in the presence of 10 U/ml heparin. However, maximal acceleration of the inhibition of activated protein C required 5-fold lower heparin concentration for rhesus monkey than for human plasma, consistent with the interpretation that the additional positive charge (E13K) in a putative-heparin binding region increased the affinity for heparin.

1 The nucleotide sequence(s) reported in this paper has been submitted to the GenBank™/EMBL Data Bank with accession number(s) U224117


 

  • References

  • 1 Marlar RA, Griffin JH. Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. J Clin Invest 1980; 66: 1186-1189
    CrossrefPubMedGoogle Scholar
  • 2 Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor: Purification from human plasma and characterization. J Biol Chem 1983; 258: 163-168
    PubMedGoogle Scholar
  • 3 Radtke K-P, Stief TW, Heimburger N. A new and simple isolation procedure for human protein C inhibitor. Biol Chem Hoppe Seyler 1988; 369: 965-974
    CrossrefPubMedGoogle Scholar
  • 4 Laurell M, Carlson TH, Stenflo JA. Monoclonal antibodies against the heparin-dependent protein C inhibitor suitable for inhibitor purification and assay of inhibitor complexes. Thromb Haemost 1988; 60: 334-339
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Pratt CW, Macik BG, Church FC. Protein C inhibitor: Purification and proteinase reactivity. Thromb Res 1989; 53: 596-602
    PubMedGoogle Scholar
  • 6 Laurell M, Christensson A, Abrahamsson P, Stenflo J, Lilja H. Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system J Clin Invest 1992; 89: 1094-1101
    CrossrefPubMedGoogle Scholar
  • 7 Stief WT, Radtke K-P, Heimburger N. Inhibition of urokinase by protein C inhibitor (PCI): Evidence for identity of PCI and plasminogen activator inhibitor 3 (PAI3). Biol Chem Hoppe Seyler 1987; 368: 1427-1433
    CrossrefPubMedGoogle Scholar
  • 8 Espana F, Berrettini M, Griffin JH. Purification and characterization of plasma protein C inhibitor. Thromb Res 1989; 55: 369-384
    CrossrefPubMedGoogle Scholar
  • 9 Laurell M, Stenflo JA. Protein C inhibitor from human plasma: Characterization of native and cleaved inhibitor and demonstration of inhibitor complexes with plasma kallikrein. Thromb Haemost 1989; 62: 885-891
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Meijers JC M, Kanters DH A J, Vlooswijk RA A, Vlooswijk HE, van Erp HE, Hessing M, Bouma BN. Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry 1988; 27: 4231-4237
    CrossrefPubMedGoogle Scholar
  • 11 Ecke S, Geiger M, Resch I, Jerabek I, Stingl L, Maler M, Binder BR. Inhibition of tissue kallikrein by protein C inhibitor. Evidence for identity of protein C inhibitor with the kallikrein binding protein J Biol Chem 1992; 267: 7048-52
    PubMedGoogle Scholar
  • 12 Griffith MJ. Heparin-catalyzed inhibitor/protease reactions: Kinetic evidence for a common mechanism of action of heparin. Proc Natl Acad Sci USA 1983; 80: 5460-5464
    CrossrefPubMedGoogle Scholar
  • 13 Pratt CW, Whinna HC, Church FC. A comparison of three heparin-binding serine proteinase inhibitors. J Biol Chem 1992; 267: 8795-8801
    PubMedGoogle Scholar
  • 14 Kuhn LA, Griffin JH, Fisher CL, Greengard JS, Bouma BN, Espana F, Tainer JA. Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor. Proc Natl Acad Sci USA 1990; 87: 8506-8510
    CrossrefPubMedGoogle Scholar
  • 15 Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z a,-antitrypsin accumulation in the liver. Nature 1992; 357: 605-607
    CrossrefPubMedGoogle Scholar
  • 16 Holmes WE, Lijnen HR, Collen D. Characterization of recombinant human a2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site. Biochemistry 1987; 26: 5133-5140
    CrossrefPubMedGoogle Scholar
  • 17 Potempa J, Shieh B-H, Travis J. Alpha-2-antiplasmin: A serpin with two separate but overlapping reactive sites. Science 1988; 2: 699-700
    PubMedGoogle Scholar
  • 18 Mast AE, Enghild JJ, Salvesen G. Conformation of the reactive site loop of arproteinase inhibitor probed by limited proteolysis. Biochemistry 1992; 31: 2720-2728
    CrossrefPubMedGoogle Scholar
  • 19 Aulak KS, Eldering E, Hack CE, Lubbers YP T, Harrison RA, Mast A, Cicardi M, Davis AE. III. A hinge region mutation in Cl-inhibitor (Ala436→Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. J Biol Chem 1993; 268: 18088-18094
    PubMedGoogle Scholar
  • 20 Madison EL, Goldsmith EJ, Gerard RD, Gething MH, Sambrook JF. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature 1989; 339: 721-724
    CrossrefPubMedGoogle Scholar
  • 21 Madison EL, Goldsmith EJ, Gerard RD, Gething MH, Sambrook JF, Bassel-Duby RS. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 1990; 87: 3530-3533
    CrossrefPubMedGoogle Scholar
  • 22 Madison EL, Goldsmith EJ, Gething MH, Sambrook JF, Gerard RD. Restoration of serine protease-inhibitor interaction by protein engineering. J Biol Chem 1990; 265: 21423-21426
    PubMedGoogle Scholar
  • 23 Perry DJ, Daly M, Harper PL, Tait RC, Price J, Walker ID, Carrell RW. Antithrombin Cambridge II, 384 Ala to Ser. Further evidence of the role of the reactive centre loop in the inhibitory function of the serpins FEBS Lett 1991; 285: 248-250
    CrossrefPubMedGoogle Scholar
  • 24 Caso R, Lane DA, Thompson EA, Olds RJ, Thein SL, Panico M, Blench I, Morris HR, Freyssinet JM, Aiach M, Rodeghiero F, Finazzi G. Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrate. Br J Haematol 1991; 77: 87-92
    CrossrefPubMedGoogle Scholar
  • 25 Ireland H, Lane DA, Thompson E, Walker ID, Blench I, Morris HR, Freyssinet JM, Grunebaum L, Olds R, Thein SL. Antithrombin Glasgow II: Alanine 382 to threonine mutation in the serpin PI2 position, resulting in a substrate reaction with thrombin. Br J Haematol 1991; 79: 70-74
    CrossrefPubMedGoogle Scholar
  • 26 Radtke K-P, Greengard JS, Fernandez JA, Villoutreix B, Griffin JH. A Two-Allele Polymorphism in Protein C Inhibitor with Varying Frequencies in Different Ethnic Populations. Manuscript submitted.
    PubMedGoogle Scholar
  • 27 Bernstein FC, Koetzle TF, Williams GJ B, Meyer Jr EF, Brice JD, Rodgers JR, Kennard O, Shimanouchi T, Tasmui M. The protein data bank: A computer-based archival file for macromolecular structures. J Mol Biol 1977; 112: 535-542
    CrossrefPubMedGoogle Scholar
  • 28 InsightII. Delphi, Homology, Discover. Anonymous ed Biosym Technologies, Inc; San Diego, CA: 1993
  • 29 Gilson M, Sharp K, Honig B. Calculating the electrostatic potential for molecules in solution. J Comp Chem 1987; 9: 327-335
    PubMedGoogle Scholar
  • 30 Harvey SC. Treatment of electrostatic effects in macromolecular modeling. Proteins 1989; 5: 78-92
    CrossrefPubMedGoogle Scholar
  • 31 Kspana F, Griffin JH. Determination of functional and antigenic protein C inhibitor and its complexes with activated protein C in plasma by ELISAs. ThrombKes 1989; 35: 671-682
    PubMedGoogle Scholar
  • 32 Meijers JC M, Vlooswijk RA A, Kanters DH A J, Messing M, Bouina BN. Identification of monoclonal antibodies that inhibit the function of protein C inhibitor. Evidence for heparin-independent inhibition of activated protein C in plasma Blood 1988; 72: 1401-1403
    PubMedGoogle Scholar
  • 33 Heeb MJ, Schwarz II P, While T, Liimmle B, Berreltini M, Grilfin JH. Immunoblotling studies of the molecular forms of protein C in plasma. Thromb Res 1988; 52: 33-43
    CrossrefPubMedGoogle Scholar
  • 34 Radtke K-P, Fermindez JA, Greengard JS, Tang WW, Wilson CB, Loskutoll DJ, Scharrer I, Ciriffin JH. Protein C Inhibitor is Expressed in Tubular Cells of Human Kidney. J Clin Invest 1994; 94: 2117-2124
    CrossrefPubMedGoogle Scholar
  • 35 Meijers JC M, Chung DW. Evidence for a Glycine Residue at Position 316 in Human Protein C Inhibitor. Thromb Res 1990; 59: 389-393
    CrossrefPubMedGoogle Scholar
  • 36 Suzuki K, Kusumoto H, Nishioka J, Komiyama Y. Bovine plasma protein C inhibitor with structural and functional homologous properties to human plasma protein C inhibitor. J Biochem 1990; 107: 381-388
    CrossrefPubMedGoogle Scholar
  • 37 Lee B, Richards FM. The interpretation of protein structure: Estimation of static accessibility. J Mol Biol 1971; 55: 379-400
    CrossrefPubMedGoogle Scholar
  • 38 Loebermann H, Tokuoka R, Deisenhofer J, Huber R. Human alpha I-proteinase inhibitor: Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol 1984; 177: 531-566
    CrossrefPubMedGoogle Scholar
  • 39 Lim WA, Farruggio DC, Sauer RT. Structural and energetic consequences of disruptive mutations in a protein core. Biochemistry 1992; 31: 4324-4333
    CrossrefPubMedGoogle Scholar
  • 40 Patthy L, Nikolics K. Functions of agrin and agrin-related proteins. Trends Neurosci 1993; 16: 76-81
    CrossrefPubMedGoogle Scholar
  • 41 Owen MC, Brennan SO, Lewis JH, Carrell RW. Mutation of antitrypsin to antithrombin: a 1-antitrypsin Pittsburgh (358 Met-> Arg), a fatal bleeding disorder. N Engl J Med 1983; 309: 694-698
    CrossrefPubMedGoogle Scholar
  • 42 Sherman PM, Lawrence DA, Yang AY, Vandenberg ET, Paielli D, Olson ST, Shore JD, Ginsburg D. Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center. J Biol Chem 1992; 267 (11) 7588-7595
    PubMedGoogle Scholar
  • 43 Austin RC, Rachubinski RA, Blajchman MA. Site-directed mutagenesis of alanine-382 of human antithrombin III. FEBS Lett 1991; 280: 254-258
    CrossrefPubMedGoogle Scholar
  • 44 Owen MC, Borg JY, Soria C, Soria J, Caen J, Carrell RW. Heparin binding deled in a new antithrombin III variant: Rouen, 47 Arg to His. Blood 1987; 69: 1275-1279
    PubMedGoogle Scholar
  • 45 Peterson CB, Noyes CM, Pecon JM, Church FC, Blackburn MN. Identification ol a lysyl residue in antithrombin which is essential for heparin binding. J Biol Chem 1987; 262 (17) 8061-8065
    PubMedGoogle Scholar
  • 46 Chang J-Y, Tran TH. Antithrombin III Basel: Identification of a Pro-Leu substitution in a heriditary abnormal antithrombin with impaired heparin cofactor activity. J Biol Chem 1986; 261 (03) 1174-1176
    PubMedGoogle Scholar
  • 47 Duchang N, Chassé J-F, Cohen GN, Zakin MM. Molecular characterization of the antithrombin III Tours deficiency. Thromb Res 1987; 45: 115-121
    CrossrefPubMedGoogle Scholar
  • 48 Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N. Antithrombin III Toyama: Replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc Natl Acad Sci USA 1984; 81: 289-293
    CrossrefPubMedGoogle Scholar
  • 49 Blackburn MN, Smith RL, Carson J, Sibley CC. The heparin-binding site of antithrombin III. J Biol Chem 1984; 259 (02) 939-941
    PubMedGoogle Scholar
  • 50 Liu C-S, Chang J-Y. The heparin binding site of human antithrombin III. J Biol Chem 1987; 262 (36) 17356-17361
    PubMedGoogle Scholar
  • 51 Ragg H, Ulshofer T, Gerewitz J. On the activation of human leuserpin-2, a thrombin inhibitor, by glycosaminoglycans. J Biol Chem 1990; 265 (09) 5211-5218
    PubMedGoogle Scholar
  • 52 Blinder MA, Andersson TR, Abildgaard U, Tollefsen DM. Heparin cofactor II Oslo: Mutation of ARG-189 to His decreases the affinity for dermatan sulfate. J Biol Chem 1989; 264 (09) 5128-5133
    PubMedGoogle Scholar
  • 53 Pratt CW, Church FC. Heparin binding to protein C inhibitor. J Biol Chem 1992; 267: 8789-8794
    PubMedGoogle Scholar
  • 54 Suzuki K, Deyashiki Y, Nishioka J, Kurachi K, Akiras M, Yamamoto S, Hashimoto S. Characterization of a cDNA for human protein C inhibitor: A new member of the plasma serine protease inhibitor superfamiiy. J Biol Chem 1987; 262: 611-616
    PubMedGoogle Scholar
  • 55 Meijers JC M, Chung DW. Organization of the gene coding for human protein C inhibitor (plasminogen activator inhibitor-3). J Biol Chem 1991; 266: 15028-15034
    PubMedGoogle Scholar